Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12955MR)

This product GTTS-WQ12955MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF12A gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016639.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51330
UniProt ID Q9NP84
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12955MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7658MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GEN-1029
GTTS-WQ7763MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ18MR IVTScrip™ mRNA-Anti-S, 2130(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ7016MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ10091MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ15134MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SYNT-001
GTTS-WQ21MR IVTScrip™ mRNA-Anti-S, 2130(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ6694MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DNIB0600A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW